Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Finance

Insilico, Lila draw nine-figure venture rounds: Finance Report

Plus: public companies Beam, Tarsus and Mineralys raise follow-ons

March 14, 2025 11:35 PM UTC

Insilico and newly launched Lila drew the week’s largest venture rounds, while at least one biotech priced a follow-on that fell short of expectations.

A new $110 million series E round will allow Insilico Medicine Inc. to begin pivotal testing of its inhalable antifibrotic therapy rentosertib (ISM001-055) to treat idiopathic pulmonary fibrosis. The product, Insilico’s most advanced in its pipeline of AI-derived treatments, has led to improvements in forced vital capacity in a Phase IIb study. The biotech has also started clinical testing of TEAD inhibitor ISM6331 to treat mesothelioma and other solid tumors...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article